Literature DB >> 18249473

Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.

Regina Appiah-Opong1, Iwan de Esch, Jan N M Commandeur, Mayagustina Andarini, Nico P E Vermeulen.   

Abstract

Inhibition of cytochrome P450 (CYP) is a major cause of drug-drug interactions. In this work, inhibitory potentials of 33 curcumin analogues, i.e. 2,6-dibenzylidenecyclohexanone (A series), 2,5-dibenzylidenecyclopentanone (B series) and 1,4-pentadiene-3-one (C series) substituted analogues of curcumin towards recombinant human CYP1A2, CYP3A4, CYP2B6, CYP2C9 and CYP2D6, all important for drug metabolism, were studied in vitro. Fluorescence plate reader and high performance liquid chromatography (HPLC) assays were used to evaluate CYP-inhibitory activities. MOE-based Quantitative structure-activity relationship (QSAR) analysis suggested that electrostatic and hydrophobic interactions and lipophilicity are important factors for CYP inhibition. Apart from insights in important molecular properties for CYP inhibition, the present results may also guide further design of curcumin analogues with less susceptibility to drug-drug interactions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18249473     DOI: 10.1016/j.ejmech.2007.10.034

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  8 in total

1.  Exploration of the binding of curcumin analogues to human P450 2C9 based on docking and molecular dynamics simulation.

Authors:  Rongwei Shi; Yin Wang; Xiaolei Zhu; Xiaohua Lu
Journal:  J Mol Model       Date:  2011-11-12       Impact factor: 1.810

2.  A novel curcumin analogue is a potent chemotherapy candidate for human hepatocellular carcinoma.

Authors:  Ji-An Zhao; Mei-Xiang Sang; Cui-Zhi Geng; Shi-Jie Wang; Bao-En Shan
Journal:  Oncol Lett       Date:  2016-09-13       Impact factor: 2.967

3.  A polymeric nanoparticle formulation of curcumin (NanoCurc™) ameliorates CCl4-induced hepatic injury and fibrosis through reduction of pro-inflammatory cytokines and stellate cell activation.

Authors:  Savita Bisht; Mehtab A Khan; Mena Bekhit; Haibo Bai; Toby Cornish; Masamichi Mizuma; Michelle A Rudek; Ming Zhao; Amarnath Maitra; Balmiki Ray; Debomoy Lahiri; Anirban Maitra; Robert A Anders
Journal:  Lab Invest       Date:  2011-06-20       Impact factor: 5.662

4.  In Vitro Antioxidant Potential and Effect of a Glutathione-Enhancer Dietary Supplement on Selected Rat Liver Cytochrome P450 Enzyme Activity.

Authors:  Benoit B N'guessan; Seth K Amponsah; George J Dugbartey; Kwabena D Awuah; Eunice Dotse; Abigail Aning; Kennedy K E Kukuia; Isaac J Asiedu-Gyekye; Regina Appiah-Opong
Journal:  Evid Based Complement Alternat Med       Date:  2018-05-24       Impact factor: 2.629

5.  Effect of Cellgevity® Supplement on Selected Rat Liver Cytochrome P450 Enzyme Activity and Pharmacokinetic Parameters of Carbamazepine.

Authors:  Seth Kwabena Amponsah; Benoit Banga N'guessan; Martin Akandawen; Abigail Aning; Sedem Yawa Agboli; Eunice Ampem Danso; Kwabena Frimpong-Manso Opuni; Isaac Julius Asiedu-Gyekye; Regina Appiah-Opong
Journal:  Evid Based Complement Alternat Med       Date:  2020-07-03       Impact factor: 2.629

6.  B19, a novel monocarbonyl analogue of curcumin, induces human ovarian cancer cell apoptosis via activation of endoplasmic reticulum stress and the autophagy signaling pathway.

Authors:  Wanglei Qu; Jian Xiao; Hongyu Zhang; Qiong Chen; Zhouguang Wang; Hongxue Shi; Liang Gong; Jianqiang Chen; Yanlong Liu; Risheng Cao; Jieqiang Lv
Journal:  Int J Biol Sci       Date:  2013-08-14       Impact factor: 6.580

7.  Inhibitor of CBP Histone Acetyltransferase Downregulates p53 Activation and Facilitates Methylation at Lysine 27 on Histone H3.

Authors:  Adam S Vincek; Jigneshkumar Patel; Anbalagan Jaganathan; Antonia Green; Valerie Pierre-Louis; Vimal Arora; Jill Rehmann; Mihaly Mezei; Ming-Ming Zhou; Michael Ohlmeyer; Shiraz Mujtaba
Journal:  Molecules       Date:  2018-08-02       Impact factor: 4.411

8.  Curcumin Derivatives Verify the Essentiality of ROS Upregulation in Tumor Suppression.

Authors:  Ikuko Nakamae; Tsumoru Morimoto; Hiroki Shima; Masafumi Shionyu; Hisayo Fujiki; Noriko Yoneda-Kato; Takashi Yokoyama; Shigehiko Kanaya; Kiyomi Kakiuchi; Tsuyoshi Shirai; Edy Meiyanto; Jun-Ya Kato
Journal:  Molecules       Date:  2019-11-10       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.